ANATOMY AND BIOLOGY OF THE PROSTATE
The prostate is a ®bromuscular gland surrounding the male urethra (see Fig. 1 ,2). It is located behind the symphysis pubis, inferior to the bladder and anterior to the rectum. The prostate is traversed by the urethra and both ejaculatory ducts. It is divided into anatomical areas and zones. The distal glandular prostate constitutes around 95% of the glandular tissue and is divided into two regions: the peripheral and central zone, comprising nearly 75% and 25% of its volume, respectively. The ®bromuscular stroma blends proximally with the detrusor muscle ®bres that surround the urethra at the bladder neck. The proximal glandular prostate consists of the transition zone, which accounts for about 5% of the glandular element, and a periurethral zone. It is of clinical importance to distinguish the transition zone from the rest of the prostate. Whilst it rarely develops a malignant cancer, it is the sole site for the development of benign prostatic hyperplasia (BPH). Histologically, the prostate is composed of non-striated ®bromuscular tissue and glandular tissue. Numerous follicles and papillae open into 12±20 excretory ducts. The ductal epithelium is responsible for production and secretion of prostate speci®c antigen (PSA). The basement membrane creates a barrier preventing escape of PSA into the peripheral circulation. It is the disruption of this barrier by disease which allows an in¯ux of PSA into the systemic circulation.
prostatitis is characterized by the abrupt onset of fever, dysuria, haematuria and urinary frequency. Most causative organisms, usually derived from the urinary tract, are sensitive to the quinolone antibiotics e.g. cipro¯oxacin.
Whilst modern antibiotics have reduced the incidence of acute prostatitis, its ability to elevate the serum PSA level has led to increased clinical prominence. 2, 3 Pansadoro et al. 4 found that 71% of men with acute prostatitis had elevations of their serum PSA, mostly in the 4± 10 mg/L range. This elevation is usually transient, lasting for about 6 weeks. 5 Chronic prostatitis, now increasingly common, runs a more indolent course and is frequently sterile. 6 Serum PSA concentrations are increased in less than 10% of patients. 4 Other non-infective causes of prostatic inammation, including urethral catheterization, acute urinary retention, prostate biopsy and prostatic massage, are also capable of causing an increase in the serum PSA concentration. 7 Serum PSA concentrations return to normal once the acute in¯ammation has subsided. Several authors have shown that standard digital rectal examination produces a small, clinically insigni®cant rise in the serum PSA.
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Benign prostatic hyperplasia Whilst BPH is one of the most common ailments affecting ageing men, with more than 60% in their sixties having histologically proven disease, only two-thirds will develop symptoms. Stromal nodules enlarge and coalesce, producing urethral compression. 9 Subsequently, the bladder undergoes secondary changes resulting in detrusor hypertrophy, ®brosis, diverticula formation and eventually detrusor failure if the disease progresses unchecked.
Symptoms are best divided into those of out¯ow obstruction and those of secondary bladder irritation, and are generally referred to as lower urinary tract symptoms (LUTS). Since there is much subjective variation in symptomatology, the objective International Prostate Symptom Score (IPSS) was developed. 10 In uncomplicated cases, investigations are usually limited to digital examination of the prostate, uro¯owmetry and measurement of the post-void residual bladder volume.
Treatment is aimed at symptomatic relief and options vary as to the best approach: watchful waiting, drug therapy and surgery. Pharmacologically, the a adrenergic antagonists were known to relieve symptoms and to have revolutionized the management of BPH.
11 They act to relax the smooth muscle in the prostate and bladder neck. Other commonly used pharmacological agents include 5-a reductase inhibitors e.g., ®nasteride. These act by preventing the conversion of FIGURE 
Sagittal diagram of the prostate. The coronal plane (C) is shown in relation to the ejaculatory ducts (E), verumontanum (V) and distal urethral segment (UD). The oblique coronal plane (OC) is shown in relation to the bladder (B) and proximal urethral segment (UP). The shaded area (FM)
represents the ®bromuscular stroma.
FIGURE 2. Oblique coronal plane in the prostate. This shows the relationships between the transition zone (T), periurethral region (U), sphincter (S), main glandular prostate (P) and verumontanum (V). The anterior ®bromuscular stroma (F), the bladder (B) and the urethra are shown (heavy line). The dashed line surrounds the stippled area representing the region of origin of benign prostatic hyperplasia.
testosterone into its active metabolite dihydrotestosterone (DHT), but appear less ef®cacious than a blockade.
12 Surgically, transurethral resection of the prostate (TURP) is the`gold standard' treatment. It has withstood many other competitors (e.g. microwave, laser, ultrasound) as well as the test of time.
Benign prostatic hyperplasia leads to an increase in prostatic size and a subsequent increase in the serum PSA concentration. Stamey et al. 13 studied the PSA of men with BPH undergoing prostatectomy. Using the Yang Pros-check assay, they attributed 0´3 mg/ L of serum PSA to each gram of prostate tissue. Hence, the concept of PSA density was introduced to differentiate a small gland with high PSA (likely to be malignant) and a large gland with a raised PSA appropriate to its size.
Adenocarcinoma of the prostate
Prostate speci®c antigen's rapid rise in prominence is due to its close association with cancer of the prostate (CaP). Whilst this is the most common cancer in Western men, its relatively slow growth allows many men to`die with the disease rather than from it'. It is third to lung and large bowel cancer, in terms of male cancer deaths. In 1995 there were 8866 registered deaths in England and Wales from prostate cancer.
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The incidence has increased rapidly in recent years, which cannot be accounted for by better diagnosis of the disease alone.
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The prevalence of prostate cancer is proportional to age. The median age of affected men is around 72 years. Not all men with CaP develop invasive disease. Autopsy studies have shown foci of CaP in up to 50±70% of men over 70 years. 16, 17 However, only 25% of these cancers are larger than 1 cm 3 in volume and likely to be signi®cant. 18 Therefore, it appears that many men have microscopic foci of adenocarcinoma, which, paradoxically, never become clinically signi®cant.
Geographically, Scandinavia has the highest worldwide incidence (Sweden=75/100 000) and the Far East the lowest (Japan=8/100 000). When racial factors are compared, however, by far the highest incidence is amongst black men in the USA (152/100 000). 15 It appears that immigrants adopt the aetiological risks of their new country rather than retain those of their original country. Geographical trends have been used to try to establish aetiology for CaP. Pollutants, dietary factors, sexual activity, venereal disease and hormonal factors have all been implicated in different studies.
19,20 Unlike breast cancer, it is clear that familial CaP is less common, accounting for possibly only 10% of cases. 21 Pathologically, adenocarcinomas represent 95% of prostate cancers, the rest consisting of sarcomas, lymphomas, squamous cell carcinomas and metastases from other sites. The majority (80%) of prostate tumours originate in the peripheral zone of the prostate, 22 the remaining few originating in the transition zone. Prostate cancer is a multifocal disease in more than 85% of prostatectomy specimens, with 70% having bilateral disease.
23 Prostatic intraepithelial neoplasia (PIN) is also found in many surgical specimens. This is characterized by cytologically atypical cells lining normal architectured ducts. Despite the close relationship between PIN and CaP, the absolute proof of PIN's natural history is lacking. However, when high-grade PIN alone is found in prostate biopsies, subsequent repeat biopsy shows CaP in 30±50%. 24 As PIN does not lead to basement membrane disruption, serum PSA is unaffected. Tumour grade has best been de®ned by Gleason and Mellinger, 25 who looked at the macroscopic glandular differentiation of the tumour (score 1± 5). An overall sum is derived by adding the ®rst and second most predominant architectures. Prognosis is proportional to the sum score (worse for high scores). After initially localized growth, the tumour penetrates the capsule along perineural and lymphatic channels to reach the periprostatic tissues. The ®rst metastases appear in the local obturator lymph nodes. Circulating tumour cells then lodge in the skeleton, forming osteosclerotic metastases. Rarely, metastases are found in the liver, bladder and adrenal glands.
With the introduction of PSA, the presentation of CaP to the clinician has changed markedly. 17 Previously, nearly all tumours presented at an advanced stage with either skeletal metastases or bladder out¯ow obstruction. Currently in the UK, over one-third of patients diagnosed with CaP presented to the urologist with only an elevated PSA. At diagnosis, 25% are found to have organcon®ned disease. 26 In the USA, where annual PSA screening has been advocated by the American Cancer Society, 27 60±75% of patients present to their urologist with organ-con®ned disease. 28, 29 Data from the USA has also shown a reduction in the mean age at diagnosis, with the use of PSA testing. 30 However, despite increasing detection and radical treatment of early disease, the overall mortality rate does not appear to have fallen. 29, 31 It is suggested that screening has merely detected these tumours earlier, without treatment in¯uencing their natural history ± so-called`lead time bias '. 32 Due to the slow growth of CaP, the answers to PSA screening trials may not be available for several years. Currently, PSA screening for CaP is not advocated in the UK, 33,34 although the test is available to men who request it, following careful counselling. Once suspected, the diagnosis of CaP is con®rmed by a biopsy performed transrectally under ultrasound guidance.
The treatment options vary with tumour stage, patient ®tness and preference. Tumours suitable for cure from radical treatment must be con®ned within the prostate capsule and have no metastases. Since the most likely site for extralymphatic spread is the skeleton, a radionucleotide bone scan is the most useful radiological investigation. Whilst direct radiological pelvic imaging [either computed tomography (CT) or magnetic resonance imaging (MRI)] can show nodal enlargement over 1 cm in size, it will understage small nodal metastases and overstage reactive lymphadenopathy. As a result, most clinicians no longer use this imaging to stage the disease. The likelihood of extracapsular spread can be estimated by a combination of clinical examination, PSA concentration and grade of tumour. 35 Recent research has raised hopes for improved staging of CaP. Using reverse transcription polymerase chain reaction (RT-PCR) for PSA mRNA, circulating prostatic epithelial cells can be identi®ed. It is hoped this will identify men with microscopic metastases who are therefore not suitable for radical prostatectomy. 36 Some authors claim that this technique can be used for`molecular staging' of prostate cancer, though reproducibility and clinical applicability remain to be con®rmed.
The treatment of CaP is complex and much debated. For organ-con®ned CaP, the options vary between watchful waiting, radiotherapy and radical prostatectomy. In our unit the patient is educated about each choice before making an informed decision. Traditionally, surgery has been the preferred treatment. The complications from radical prostatectomy include erectile dysfunction (30%), urinary incontinence (8%) and mortality (0´2%). 37 Radical radiotherapy offers an alternative to surgery. This can be external beam or by implant of radioactive seeds (brachytherapy). Whilst radiotherapy avoids surgery, it also has signi®cant associated morbidity and mortality. Radiotherapy has never been proven in a clinical trial to be as ef®cacious as surgery, although retrospective studies show comparable outcomes. 38 In watchful waiting, as the name suggests, treatment is only initiated for symptoms that develop from tumour growth. Because CaP is often slow growing, and radical treatment has signi®cant morbidity, some patients choose watchful waiting, accepting continued quality of life rather than potentially increased quantity of life. Chodak 39 conducted a meta-analysis of 828 patients treated by watchful waiting. Eightyseven per cent of patients with Gleason score < 8 were alive at 10 years. In locally advanced disease, radical radiotherapy can be offered, with or without adjuvant androgen withdrawal. In metastatic prostate cancer, conventional treatment is by androgen withdrawal. The duration and degree of tumour regression following testosterone withdrawal is unpredictable, in some men lasting decades. However, most patients will escape hormonal control of the disease between 2±3 years following initiation of therapy, and will have a subsequent limited life expectancy of 6±9 months. Commonly used methods of androgen ablation include gonadotrophin-releasing hormone (GnRH) analogues, surgical castration, and non-steroidal anti-androgens.
BIOCHEMISTRY OF PSA
Prostate speci®c antigen is a 28 400 Da glycoprotein 40 comprising 237 amino acid residues 41 with ®ve inter-chain disulphide bonds and approximately 8% carbohydrate in the form of a N-linked oligosaccharide sidechain. In seminal plasma PSA can be shown to exist in ®ve isoforms, two biologically active and differing in the degree of glycosylation, and three biologically inactive or`nicked' forms. 42 This inherent heterogeneity has proved problematic in the various puri®cations, and some procedures have not yielded a product in which all isoforms are represented. Prostate speci®c antigen exhibits serine protease activity (EC 3.4.21.77) similar to chymotrypsin. 43 Prostate speci®c antigen is a member of the human kallikrein family, with which it shares considerable structural and functional homology and a gene location on the long arm of chromosome 19 (19q13.2±q13.4).
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Prostate speci®c antigen, redesignated as hK3 in conformity with the uni®ed nomenclature of the kallikreins, has 80% sequence homology with hK2 (glandular kallikrein) and 63% with hK1 (pancreatic±renal kallikrein). 45 Monoclonal antibodies to PSA have been classi®ed by the International Society for Oncodevelopmental Biology and Medicine (ISOBM) TD-3 workshop 46 into six major groupings by cross inhibition, af®nity constant determination and by assay pairing. Group 1 consists of those antibodies reactive with the f-PSA (free PSA) epitope, whilst groups 2±6 are reactive with the epitopes in the complexed forms. Antibodies classi®ed into groups 3 and 6 have been shown to cross-react with epitopes on hK2. 47 Paradoxically, human serum kallikrein is not a member of this gene family and has no structural homology with PSA.
Prostate speci®c antigen is synthesized in the ductal and acinar epithelium of the prostate gland, whence it is secreted into the seminal plasma at a concentration of 0´5±2´0 g/L; 48 secretion has been identi®ed in the paraurethral and perianal glands as well as in apocrine sweat glands and the mammary glands. Synthesis of PSA has also been demonstrated in a number of tumour cell-lines, notably neuroblastoma. 49 The function of PSA is to liquefy the seminal coagulum by proteolysis, with release of the entrapped spermatozoa, 50 and may have a bioactive role in fertilization. 51 In relation to carcinoma of the prostate the literature is confusing and even contradictory, with evidence promoting both its stimulatory and inhibitory role. 52 It has been shown that PSA can cleave insulin-like growth factor binding protein-3
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[liberating bioactive insulin-like growth factor (IGF-1)], 54 activate the transforming growth factor (TGF-b) 55 and regulate the bioactivity of parathyroid hormone-related protein. 56 Recent experimental evidence suggests that PSA may also have antiangiogenic activity by inhibition of endothelial cell proliferation induced by ®bro-blast growth factor (FGF-2) and vascular endothelial growth factor (VEGF). 57 PSA has also been shown to release angiostatin-like fragments from plasminogen.
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Free and complexed PSA The predominant molecular form present in blood plasma is the 80±90 kDa complex of PSA with a1-antichymotrypsin (ACT); free PSA represents a small but variable proportion of the total PSA (t-PSA) concentration. Minor fractions of PSA exist as complexes with other protease inhibitors, predominantly a2-macroglobulin (A2M), inter-a-trypsin inhibitor (IATI) and, at high concentrations, a1-antitrypsin (AAT). In seminal plasma, some 5% of the PSA is complexed with protein C inhibitor (PCI). 45 Whilst all commercial assays for PSA recognize free PSA (f-PSA) the PSA±ACT and PSA±AAT complexes, 59 and possibly also the PSA±IATI complex, none recognize the PSA± A2M complex in which the PSA molecule is interiorized by the altered conformational structure of the inhibitor. 60 It can be shown that, in vitro, up to 60% of seminal plasma derived f-PSA will bind to A2M in 1±3 hours at 37°C, the binding to ACT taking about 24 hours, and that to AAT 48 hours. f-PSA is mainly in the biologically inactive or`nicked' form, with cleavage of the polypeptide chain between residues 85±86, 145±146 or 182±183, 61 and in this state will not bind to the protease inhibitors. The nicked or inactive forms of f-PSA are present in higher proportions in BPH than in CaP. 62 Additional sites for internal cleavage of the molecule have been described between residues 54±55, 57±58 and 146±147 in PSA derived from BPH nodular¯uids.
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Whereas all diagnostic companies in the ®eld have assays for total PSA, many also have assays speci®c for the free PSA, reactive with both the active and the`nicked' forms. Assays are also available for the PSA±ACT complex but on only a limited number of analytical platforms.
The concept of equimolarity
Assay discrepancies may result from differences in antibody speci®city and af®nity, reaction kinetics or calibration. Although differences due to calibration have been minimized in recent years by the National Committee for Clinical Laboratory Standards (NCCLS) recommendations 64 and programmes by both the Institute of Reference Methods and Materials of the European Community (IRMM) and the World Health Organization (WHO) to certify reference materials or standards, differences related to reaction kinetics and antibody speci®city remain. These are a direct result of the multitudinous molecular forms in which PSA exists in the serum.
Prostate speci®c antigen has ®ve major epitope domains. Four of these domains have been tentatively localized to amino-acid residues 1±13, 53±64, 80±91 and 151±164, 65 with antibodies speci®c to f-PSA binding to the kallikrein loop between residues 84±91. The latter domain incorporates the active site and is blocked by complexing with ACT. In the PSA±ACT complex a further domain is affected by a variable degree of steric hindrance to antibody binding. 66 This phenomenon affects the molar response of free and complexed PSA, with the result that some antibodies (and assays) show a marked preference for binding f-PSA and give relatively less signal per unit mass of complexed PSA.
Assays formulated with two (monoclonal) antibodies directed against epitope domains unaffected by ACT binding will give an equivalent signal with both free and complexed PSA and this is considered as equimolar. The molar equivalence of an assay may also be affected by reaction kinetics, the shorter incubation times favouring antibody binding to the smaller molecular weight f-PSA. Shortening of the incubation time in an equimolar assay (Hybritech TANDEM-R, see Appendix 1 for details) from the recommended 120 min to 15 min results in signi®cant skewing of the assay in favour of f-PSA. 67 A similar pattern may be seen with the two t-PSA assays available on the DPC Immulite immunoassay platform,`total PSA' and the`3rd generation' PSA; using these assays, with the same antibody pairing albeit in a reversed sequence, the longer incubation of thè 3rd generation' assay gives an equimolar response in contrast to the skewed response in the`total PSA' assay.
The gradual adoption by industry of a 90:10 mixture of PSA±ACT complex and f-PSA as the calibrator for t-PSA assays 68 has minimized the differences that were previously apparent between equimolar and non-equimolar assays in clinical samples.
The discrepancy in values obtained between equimolar and skewed assays is dependent on the ratio of free to total PSA in the clinical sample, and will become increasingly apparent as the ratio increases above 15%. The Yang Pros-Check 2 assay, a competitive binding radioimmunoassay with polyclonal antibody, gave results which were signi®cantly higher than the Hybritech TANDEM-R. 68 The same effect was reported, for some clinical samples, for the Bayer ACS-180 2 PSA assay. 69 The calibrator in this assay was changed from free PSA to the 90:10 complex to give the PSA-2 format. The resultant effect was to minimize the differences between clinical samples without altering the inherent non-equimolarity induced by a combination of the antibody pairing and the assay kinetics. Nagasaki et al. 70 de®ned the degree of skewness in the Abbott IMx monoclonal/ polyclonal assay, now withdrawn, as [t-PSA]=[f-PSA/0´55+c-PSA]. This (almost) two-fold over-representation of f-PSA would not have made any signi®cant differences in clinical interpretation of t-PSA concentrations in most situations 71 but would have caused erroneous interpretations of the f-PSA:t-PSA ratios.
PSA ASSAYS
Most of the total PSA assays currently available on the UK market are formulated for use on speci®c immunoassay platforms, and the assay appears in the repertoire of all major instrument platforms (see Appendix 1) . A decreasing minority of assays is available as open systems' that can be used without speci®c instrumentation. Table 1 includes the assays for total, free and complexed PSA that are in current use by participant laboratories in the UK National External Quality Assessment Service (NEQAS) for PSA or have been subjected to formal evaluation by the Medical Devices Agency (MDA). Capture antibody refers to the initial antibody in the reaction, usually bound to the solid phase. Tracer antibody refers to the second antibody of the immunometric assay, complexed with the relevant tracer particle or system. Differences in the molar responsiveness of assays for t-PSA will have a signi®cant in¯uence on the interpretation that can be placed on any individual PSA value. With the increased proportion of f-PSA in benign hyperplasia and prostatitis, the bias induced in the skewed assays will potentially lead to an increase in false positive results. 94, 95 The skewed t-PSA assay will distort the PSA index (f-PSA expressed as a percentage of t-PSA) to an extent that may have clinical relevance and can only be partially corrected by the use of assay-speci®c threshold values. 96 Whilst the general tenet that equimolarity of response demands appropriate monoclonal antibody selection, and that polyclonal antibodies favour a non-equimolar response, is true, it should be noted that attention to antibody selection and assay kinetics can produce an equimolar response with polyclonal antibodies incorporated in the assay as with the Bayer Immuno-1 and DPC 3rd generation assay. 97 Various publications 95, 98, 99 have con®rmed the UK NEQAS observations that the Abbott IMx monoclonal/polyclonal antibody assay, the Bayer ACS-180 PSA-1 and PSA-2 and the DPC Immulite Total PSA assays are not equimolar and overestimate the f-PSA to a variable extent. These assays cannot be used in calculation of a PSA index with any reliability. It should be emphasized that the Abbott IMx monoclonal/ polyclonal assay has now been withdrawn in favour of the Total PSA assay, a dual monoclonal assay, which is equimolar, and that the DPC 3rd generation PSA assay available on the Immulite and Immulite 2000 platforms is also equimolar. An equimolar assay for the Bayer ACS-180 and ADVIA Centaur E-PSA was introduced during 2000 and will gradually replace the earlier skewed response assays on these platforms.
Sensitivity
After radical prostatectomy the serum PSA concentration should fall to below 0´01 mg/L within 4 weeks, rises above that level being indicative of recurrent disease. 100 For the patient whose PSA level remains below 0´01 mg/L at 3 years, the probability of relapse is only 8%. 101 Yu et al. con®rmed that increases in PSA in the 0´001±0´1 mg/L range in the 3 years after radical prostatectomy were associated with relapse and a poor prognosis. 102 PSA concentration of 0´06 mg/L has been estimated to equate to a residual cancer volume of 0´02 cm. 103 Commercial assays for total PSA have very variable lower limits of detection, ranging from 0´003 mg/L to 1´0 mg/L. Table 1 shows minimal detectable levels either as determined in the MDA evaluations or those claimed by the manufacturer. In the evaluations, minimal detectable levels were determined by multiple replicate analysis of PSA free serum (PSA stripped serum, normal female blood donors or zero calibrator as advised by the manufacturer).
Calibration
The majority of commercial assays now show traceability of their calibration to the Stanford University Reference Materials with the 90:10 mixture of PSA±ACT complex and f-PSA. This has largely removed the marked inter-assay variation in t-PSA values that was seen as recently as 3 years ago. This material, prepared in accordance with the NCCLS document, 64 Complexed PSA (c-PSA) assays show traceability to the Stanford University Reference Material for PSA±ACT, even though it is accepted that one, the Bayer Immuno-1 assay, also recognizes PSA±AAT complexes to some 5% of the total. 107 Stability studies conducted during the course of the multicentre evaluation of the candidate preparations showed no detectable loss of immunoreactivity at +4°C and +20°C, but signi®cant loss at higher temperatures. From this data it is possible to predict a degradation rate at 2 20°C of 0´042% per year for the f-PSA preparation 96/668 and 0´027% per year for the 90:10 PSA preparation 96/670. 105 
Reference ranges
The often quoted upper reference limit of 4 mg/L was derived from 472 men with no history of prostate disease, 85% of whom were under 50 years of age. Using the original Hybritech assay, 4 mg/L represented the 99th centile of the study population. 108 With the Yang assay the upper reference limit, expressed statistically as the mean+2 standard deviations (SD), was quoted as 2´5 mg/L. 13 Differences in the quoted upper reference limits were not so much a matter of standardization as of the means of calculation of the reference limits. The distribution of PSA values in the normal population is such that the 99th centile exceeds the mean+2 SD by an average of 1´5±2´0-fold. 109 Age-speci®c reference ranges were introduced as a stratagem to improve speci®city in the older age groups whilst maintaining sensitivity in the younger age group (see Table 2 ). Dalkin et al., 110 Oesterling et al. 111 2´5  2´0  50±59  3´5  3´0  60±69  5´0  4´5  70±79  6´5  5´5  80±89 7´5 6´5
Ranges represent a compilation of the literature based on the Hybritech TANDEM-R assay corrected for the World Health Organization standard for PSA.
with age. Oesterling et al. 111 showed that PSA concentration was directly correlated with prostate volume, and that both were correlated with patient age. The use of age-speci®c reference ranges can maintain the sensitivity for prostate cancer detection at the same level as achieved with the 4 mg/L cut-off for patients up to 60 years, but thereafter the sensitivity falls to 50% by the age of 75 years. There is an overall increase in speci®city, and a decrease in the number of older men recommended for biopsy, but at an undetermined cost of missed cases of prostatic cancer. An alternative approach 112 used twelve times the age-related median value as a threshold for an 85% detection rate with only 0´5% false positives across all ages.
The higher prevalence and earlier age of onset of prostatic cancer reported in the AfroCaribbean populations has lead to the proposal of reference ranges that are speci®c for the ethnic origin as well as the age of the patient (see Table  2 ). The high-risk status of this population requires the sensitivity of detection to be maintained at the 95% level at the expense of speci®city. 113 Reference intervals for f-PSA are poorly documented but it would appear that, as for t-PSA, there is a positive correlation with age. 114 From the limited data currently available, it would appear that there is no signi®cant variation in PSA index (free:total ratio) with age. 114, 115 PSA is complexed by serine protease inhibitors but acute phase increases in AAT and ACT have no in¯uence on the measured PSA concentration or the free:total PSA ratio. There does, however, appear to be a negative correlation between PSA and A2M that may achieve clinical signi®cance in patients with the nephrotic syndrome.
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PSA index
The PSA index is de®ned as free PSA expressed as a percentage of total PSA. Lower proportions of f-PSA are seen in carcinoma than in benign hyperplasia. 117 For t-PSA concentrations between 4 mg/L and 20 mg/L, a PSA index of > 25% has a probability of carcinoma of < 10%, whilst a PSA index of < 10% has a probability of carcinoma of > 80%. 118 Adopting the > 25% threshold is reported to reduce the negative biopsy rate by 30% at an acceptable loss of sensitivity. 119 A 16% threshold was advocated by Leung et al. 115 as improving sensitivity and speci®city over t-PSA alone although the data are subject to some caveats in that the study used f-PSA and t-PSA assays from different manufacturers. Using an 11% threshold, Morote et al. 120 showed that there was a signi®cant increase in sensitivity over t-PSA alone, and that organ-con®ned disease with a good prognosis had higher PSA index values than disease in which there was capsular penetration and dissemination. With an 8% threshold, a sensitivity of 95% can be achieved but only at a speci®city of 44%. 121 The trend towards using a threshold value of 3 mg/L t-PSA as an indicator for biopsy can be justi®ed if a low index value of 10% is also required. 122 Computer modelling with logistic regression analysis shows that, for a patient with a normal digital rectal examination (DRE), a t-PSA of 3 mg/L and a PSA index of 10%, the probability of prostate cancer is 30%, rising to 50% with an index of 5% at the same t-PSA concentration. 123 Catalona et al. 124 observed that, for a standard 90% detection rate, the discriminant PSA index of 13% for a prostate gland of less than 40 g needed to increase to 21% for glands over 40 g. Pearson et al. 125 showed that, whilst the PSA index remains stable with increasing age, it is signi®cantly lower in men with prostate cancer than in normal individuals and men with BPH, and that this may be apparent for up to 8 years prior to diagnosis.
It would appear, however, that the PSA index is only valid for concentrations of t-PSA between 3±10 mg/L, and that the discriminant values are assay-speci®c. The calculation of a PSA index is also only valid when the constituent PSA concentrations are derived from matched assays with the same calibration, 126 and the t-PSA assay has an equimolar response. 95 This is supported by the differing opinions expressed by Pannek et al., 127, 128 who found no association between PSA index values and clinical stage when using unrelated assays from two separate manufacturers, 127 but a signi®cant association when using matched assays from a single manufacturer. 128 Similar indices can be derived from c-PSA and t-PSA, with equal clinical effect, 129, 130 although it has been suggested that the assay of c-PSA alone will give similar diagnostic potential at lower operational cost. 131 The data to support this hypothesis are limited and have not yet been subjected to the extensive independent evaluation that has supported the free:total ratio. 132 The assay of f-PSA in patients with established metastatic or late stage disease may give misleading results. In some patients the f-PSA and PSA index rise anomalously, with a concomitant decrease in the proportion of c-PSA. It is assumed that this represents the overproduction of`nicked' PSA, with its inability to bind to serine protease inhibitors.
PSA density
Prostate speci®c antigen density is the ratio of PSA concentration to prostate volume as determined by transrectal ultrasound, 133 higher values being associated with prostate cancer and lower values being associated with benign hyperplasia. Its potential value is in those men who have a PSA in the 4±10 mg/L range and have a normal DRE. 134 Although densities in excess of 0´15 are considered suggestive of malignancy, 135 clinical studies have not shown any advantage in diagnostic sensitivity. Various factors are known to in¯uence the reliability of the PSA density; these include variability in the transrectal ultrasound measurements, the shape of the gland (which will in¯uence the calculation of gland volume), and variation in the proportion of stroma to epithelial tissue within the gland.
Whilst a 5 cm 3 cancer in a 40 cm 3 gland may give a high PSA density, the same 5 cm 3 cancer in an 80 cm 3 gland will give a lower PSA density and escape detection. This apparent anomaly is in keeping with the failure of PSA density to add to the diagnostic sensitivity achieved by the combination of PSA index and PSA velocity.
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PSA velocity
This concept was introduced as an outcome of the Baltimore Longitudinal Study of Aging 137 as a further index in the differentiation of benign from malignant disease. Prostate speci®c antigen velocity is de®ned as the change in PSA concentration over time, and should be estimated over a minimum of three samples with an interval of 12 to 18 months between individual PSA values. 135 The median increase in a diseasefree population has been de®ned as 0´09 mg/L per year, although Oesterling et al. 111 reported a value of 0´04 mg/L per year. Velocities in excess of 0´75 mg/L per year are considered indicative of malignancy.
The approach places considerable demands on assay stability and consistency over time, and the careful timing of sample collection to avoid other extraneous elevations of PSA.
PSA half-life
Attempts at elucidating the half-life of PSA and f-PSA after radical prostatectomy have proved complex because of the need to allow for haemodilution effects during surgery and the attendant blood loss. 138 Best estimates suggest a half-life for t-PSA of 3 days, and for f-PSA of 0´8 days. Initial estimates based on ®rst order kinetics 137 have been superseded by a twocompartment model with an initial half-life of 1´2 and 7´5 h for f-PSA and t-PSA, respectively. 139 The second phase of decay extends to 22 and 33 h, respectively. Another study has estimated the half-life of f-PSA as 110 min.
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PSA doubling time
The use of ultrasensitive assays provides the ability to detect recurrence of prostate carcinoma months, if not years, earlier than is possible with conventional assays. 141 These assays also permit the estimate of doubling times as an estimate of tumour virulence. 
Effect of drugs on PSA levels
The 59a-reductase inhibitor ®nasteride will reduce both the t-PSA and f-PSA by up to 50%, but will not induce any change in the PSA index. 144 These changes may be seen both in benign hyperplasia and in prostate carcinoma, but are not consistent and may not affect all patients to an equal degree. This variability in effect makes the interpretation of PSA values in patients treated with ®nasteride somewhat complex.
Caveats of sample collection Preanalytical factors
Blood samples should be taken into plain containers without anticoagulant. There would appear to be no contraindication to the use of serum-separator gels and clot promoters in the blood collection tubes. No commercial assay available in the UK is currently validated for use with plasma of any type.
Samples for PSA assay should be collected prior to DRE or prostatic massage as both procedures cause some elevation of the PSA, maximal between 30 and 60 min after the examination. It is unlikely that the induced elevation would be of clinical signi®cance but a post-examination interval of 3 days is recommended. 145 Transrectal ultrasound and cystoscopy have been reported as inducing minor elevations of PSA which return to normal within 3 days. An interval of at least 1 week is recommended prior to blood sampling.
Needle biopsy of the prostate and transurethral resection will induce marked elevations of PSA of up to 50-fold. Whilst levels fall to baseline within 12±30 days, 146 a delay of 6 weeks is recommended.
Exercise for 15 min on a bicycle ergometer will increase the PSA by threefold, but exercise on a treadmill produces no similar effect. Whilst clinically relevant changes in PSA are unlikely, cycling should be avoided for 24 h prior to blood sampling.
Prostate speci®c antigen is increased following ejaculation, maximal levels being attained after 60 min. Sexual abstinence for 24 h prior to blood sampling should be recommended. 147 
PSA stability
Total PSA concentrations in serum have been shown to decrease at approximately 1´5% per month at 4°C 95 and f-PSA concentrations to increase at a similar rate 148 owing to the gradual degradation of PSA±ACT (c-PSA). Total PSA is, however, stable at 2 20°C for more than 8 months. Serum samples should be separated from the clot within 16 h and stored at 2 20°C until assayed. Total PSA and c-PSA appear to be robust in terms of freeze±thaw cycles and reports suggest that PSA is stable for at least 5±6 cycles.
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External quality assessment performance External quality assessment services for PSA assays are available from Bio-Rad Laboratories (Bio-Rad EQAS), Randox Laboratories (RI-QAS) and UK NEQAS for immunology (see Appendix 2). All include t-PSA in their repertoires, whilst Bio-Rad and UK NEQAS also include f-PSA and free:total PSA ratio. Most external quality assessment and pro®-ciency testing surveys show similar ®ndings in respect to the performance of the various assay kits. The majority of commercial assays now agree numerically in terms of the c-PSA content of the survey samples. The higher values are seen in those assays which have the skewed reactivity in relation to the free forms of PSA. This is well demonstrated in the New York State Pro®ciency Testing Surveys, the College of American Pathologists (CAP) Ligand Assay Surveys and in some UK NEQAS distributions where the samples are made by addition of free PSA to a human plasma matrix, 149 but are less evident in CAP reference materials and those UK NEQAS samples made from endogenous PSA.
Medical Devices Agency evaluations
The Medical Devices Agency (MDA) kit evaluation unit has been established to perform critical Sensitivity, speci®city, positive predictive value (PPV%) and negative predictive value (NPV%) in relation to the de®ned test serum panel, using the threshold as de®ned by the manufacturer. CV%=between-assay imprecision achieved in the Medical Devices Agency evaluation at a PSA concentration of 4 mg/L.
and independent evaluations of diagnostic assay kits available to UK clinical laboratories. Two series of PSA kits have been evaluated in terms of their accuracy, reproducibility and performance, the reports being published by the MDA in their on-going series.
72±93
The ®rst series 72,74,75,77,79,81,83,85±90,92,93 used an identical panel of samples in the evaluation of ®fteen kits for total PSA. 150 The serum panel included samples from patients with de®ned prostate disease and other malignancies, as well as normal individuals and patients with an assortment of biochemical and pharmacological anomalies that have been recorded as producing anomalous results in immunoassay. All kits showed acceptable levels of imprecision and linearity and no`high dose hook' effects were noted up to 2000 mg/L PSA. No signi®cant interferences were noted with serum samples containing bilirubin levels > 200 mmol/L, triglyceride levels > 10 mmol/L, total protein levels > 100 g/L or haemoglobin levels > 1 g/L. The sensitivity percentage, speci®city percentage, positive predictive value (PPV%) and negative predictive value (NPV%) in relation to the panel of biopsy proven cases of prostate cancer, benign prostatic hyperplasia and prostatitis are shown in Table 3 .
A second series of evaluations 73, 78, 80, 82, 84, 91 examined the available kits for free PSA together with their relevant matched total PSA assay. 151 All total PSA kits, and the majority of free PSA kits, showed acceptable levels of imprecision and linearity. No`high dose hook' effects were noted up to 5000 mg/L PSA in both the total and free PSA assays. No signi®cant interferences were noted with a similar panel of serum samples with bilirubin, triglyceride, total protein or haemoglobin above the de®ned levels. The clinical samples used in this series of evaluations were selected to exclude those with total PSA > 10 mg/L and so mimic the dif®cult diagnostic area in routine clinical practice. Table 4 contrasts the PPV% of total PSA with that of the PSA index obtained with the matched assay pairs; in all instances, the interpretative thresholds used were those recommended by the manufacturers in their package inserts.
CONCLUSIONS
After initial diagnosis and treatment, PSA plays a vital role in the follow-up of CaP. Serial PSA measurements demonstrate the growth characteristics of each tumour. Thus CaP control, recurrence or hormonal escape can be determined. This allows detection and treatment of skeletal metastases prior to skeletal fracturing. Second line treatments can then be introduced prior to the onset of symptoms.
In summary, PSA has revolutionized the clinical care of prostate cancer. It is vital to the diagnosis and subsequent follow-up of the disease. It is hoped that it will be useful in screening for the disease. 
